Doutor Nichires Holdings Co., Ltd. (3087) AI Stock Analysis

• Market Cap: ¥114.34B
• Dividend Yield: 1.91%
• Average Volume (3M): 91.12K
• Price to Earnings (P/E): 17.2
• Beta (1Y): 0.32
• Revenue Growth: 6.24%
• EPS Growth: 12.61%
• Country: JP
• Employees: 2,765
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Restaurants
• EPS (TTM): 47.83
• Shares Outstanding: 45,609,760
• 10 Day Avg. Volume: 85,320
• 30 Day Avg. Volume: 91,123
• PEG Ratio: 0.59
• Price to Book (P/B): 1.01
• Price to Sales (P/S): 0.70
• P/FCF Ratio: 16.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥2,796.00
• Price Target Upside: 8.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 70 Outperform
• Price Target: ¥2,796.00 ▲(8.33% Upside)

Doutor Nichires Holdings Co., Ltd. receives a strong overall stock score driven primarily by its robust financial performance, including solid revenue growth and a strong balance sheet. Technical analysis presents mixed signals, with short-term weakness but long-term support, while valuation indicates the stock is fairly priced with a moderate dividend yield.

Doutor Nichires Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

DOUTOR NICHIRES Holdings Co., Ltd. manages restaurants and cafes in Japan. It manufactures and sells bread and pastry products; roasts and sells coffee; and imports, exports, purchases, and sells food products. The company also engages in the manufacture and wholesale of confectionary products; operation of bakery shops; wholesale of coffee machines, etc.; wholesale of fruits and vegetables; processing and wholesale of meat; manufacture of hams, sausages, and bacons; manufacture and wholesale of dressing products; and import of coffee beans and tea. In addition, it designs, constructs, maintains, and cleans stores; and operates natural food stores. DOUTOR NICHIRES Holdings Co., Ltd. was founded in 2007 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Doutor Nichires Holdings Co., Ltd. generates revenue primarily through its extensive network of coffee shops and retail operations. The company makes money by selling coffee beverages, food items, and packaged coffee products to customers in its stores. Additionally, Doutor Coffee's brand recognition and quality offerings contribute to attracting a steady flow of customers, which is a significant revenue stream. The company also benefits from strategic partnerships and collaborations that enhance its product offerings and market reach. Furthermore, revenue is supplemented through franchise operations, enabling expansion without significant capital expenditure.

Doutor Nichires Holdings Co., Ltd. Financial Statement Overview

Summary

Doutor Nichires Holdings Co., Ltd. exhibits a strong financial performance with solid revenue growth, improved profit margins, and robust cash flow metrics. The balance sheet is strong with low leverage, indicating prudent financial management and a positive outlook for continued success.

Income Statement

Doutor Nichires Holdings Co., Ltd. has demonstrated strong revenue growth over the past years, with a notable recovery from past losses. The company's gross and net profit margins have improved significantly in recent years, reflecting effective cost management and increased efficiency. The EBIT and EBITDA margins have also shown positive trends, indicating robust operational performance.

Balance Sheet

The company maintains a strong financial position with a low debt-to-equity ratio, reflecting prudent financial management and low leverage risk. The equity ratio indicates a solid capital structure with substantial shareholder equity backing the company's assets. The return on equity has improved, showcasing enhanced profitability and efficient use of equity capital.

Cash Flow

Doutor Nichires Holdings has consistently generated positive operating cash flows, which have supported its investment activities and capital expenditures. The free cash flow growth rate is strong, suggesting healthy cash generation and potential for reinvestment or shareholder returns. The operating cash flow to net income ratio reflects a robust cash conversion cycle.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	151.23B	148.82B	140.63B	126.86B	109.36B	96.14B
Gross Profit	90.45B	89.62B	84.19B	74.77B	64.31B	55.77B
EBITDA	13.82B	13.94B	11.72B	6.88B	7.63B	-4.40B
Net Income	6.58B	6.88B	5.49B	3.43B	1.22B	-10.98B
Balance Sheet
Total Assets	133.54B	134.23B	127.79B	121.04B	118.23B	115.25B
Cash, Cash Equivalents and Short-Term Investments	33.34B	38.99B	35.80B	32.22B	34.55B	26.31B
Total Debt	2.04B	2.11B	2.77B	1.71B	1.54B	1.31B
Total Liabilities	32.33B	29.88B	28.32B	24.75B	24.12B	21.25B
Stockholders Equity	100.86B	104.00B	99.15B	96.01B	93.86B	93.78B
Cash Flow
Free Cash Flow	0.00	6.49B	6.87B	-221.00M	10.22B	-8.06B
Operating Cash Flow	0.00	12.35B	11.79B	5.17B	14.64B	-2.88B
Investing Cash Flow	0.00	-6.23B	-4.90B	-5.59B	-4.93B	-5.95B
Financing Cash Flow	0.00	-2.93B	-3.37B	-1.98B	-1.50B	-2.15B

Doutor Nichires Holdings Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2581.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3087, the sentiment is Neutral. The current price of 2581 is below the 20-day moving average (MA) of 2653.05, below the 50-day MA of 2588.94, and above the 200-day MA of 2485.94, indicating a neutral trend. The MACD of 5.19 indicates Positive momentum. The RSI at 40.42 is Neutral, neither overbought nor oversold. The STOCH value of 9.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:3087.

Doutor Nichires Holdings Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3087	70 Outperform	¥114.34B	17.18	―	1.91%	6.24%	12.61%
8153	70 Outperform	¥121.02B	34.14	5.83%	0.76%	4.32%	29.02%
2695	66 Neutral	¥131.26B	58.57	5.53%	0.60%	5.43%	-62.27%
7630	66 Neutral	¥147.49B	45.43	9.90%	1.73%	10.63%	22.33%
9887	54 Neutral	¥113.57B	41.83	4.79%	0.40%	21.94%	-7.70%
7412	46 Neutral	¥117.02B	145.68	7.26%	―	-7.26%	―
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%

Doutor Nichires Holdings Co., Ltd. Corporate Events

Doutor Nichires Holdings Reports Mixed Financial Results for Q1 2025

Doutor Nichires Holdings reported a 6.5% increase in net sales for the three months ending May 31, 2025, compared to the previous year. However, the company experienced declines in operating profit, ordinary profit, and profit attributable to owners, reflecting challenges in maintaining profitability. The forecast for the fiscal year ending February 28, 2026, shows modest growth in net sales and profits, indicating cautious optimism for future performance.

Doutor Nichires Completes Treasury Share Acquisition

Doutor Nichires Holdings Co., Ltd. has completed the purchase of 505,800 treasury shares, totaling approximately ¥1.35 billion, as part of a resolution by the Board of Directors. This move is part of a broader strategy to purchase up to 3.5 million shares, aiming to enhance shareholder value and optimize capital structure.

Doutor Nichires Holdings Initiates Treasury Share Disposal for Director Incentives

Doutor Nichires Holdings Co., Ltd. has announced the disposal of treasury shares as part of its Restricted Stock Compensation Plan, aimed at incentivizing directors to enhance corporate and shareholder value. This move is expected to strengthen the alignment of directors’ interests with those of shareholders, potentially impacting the company’s long-term market positioning positively.

Doutor Nichires Holdings Announces Treasury Share Purchase

Doutor Nichires Holdings Co., Ltd. announced the purchase of 811,000 treasury shares at a cost of ¥2,214,532,400 between April 15 and April 30, 2025, as part of a broader plan approved by the Board of Directors to acquire up to 3.5 million shares. This strategic move, executed on the Tokyo Stock Exchange, is expected to enhance shareholder value and optimize the company’s capital structure.